David A. Stevens, M.D.; Thomas F. Waddel, M.D.; Thomas C. Merigan, M.D.
This content is PDF only. Please click on the PDF icon to access.
Fifty-three patients with disseminated herpes zoster were studied; 20 of them received intravenous cytosine arabinoside. Experience with an early treatment (first 2 days of dissemination) program suggested cytosine arabinoside shortened dissemination compared with untreated patients seen previously. With increased referral of early disseminated cases, the study population changed to include a greater proportion with milder disease. A double blind study was initiated and is currently in progress. To date, the results (11 patients) in the placebo and cytosine arabinoside groups aren't significantly different. Treatment with cytosine arabinoside shortens dissemination in some patients destined to have prolonged dissemination and visceral complications:
Learn more about subscription options.
Register Now for a free account.
Stevens DA, Waddel TF, Merigan TC. Effect of Cytosine Arabinoside on Disseminated Herpes Zoster and Vesicle Fluid Interferon.. Ann Intern Med. 1972;76:873. doi: 10.7326/0003-4819-76-5-873_1
Download citation file:
Published: Ann Intern Med. 1972;76(5):873.
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only